Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Complications of HIV Disease and its Therapy

With the advent of more effective antiretroviral therapy, people with HIV are living longer. As a result, clinicians are paying increased attention to co-morbidities, aging-related complications, and long-term toxicities of antiretroviral therapy in this population.  A major focus of my clinical research effort has been the investigation of metabolic complications in people living with HIV, including lipid elevations that may predispose to accelerated cardiovascular disease, body shape changes known as lipodystrophy, and disorders of glucose metabolism.  We are also conducting studies in the areas of aging-related complications and emphysema in people living with HIV.  I have active collaborations with colleagues in the Division of Geriatrics and Palliative Medicine, the Division of Pulmonary and Critical Care Medicine, and in the College of Human Ecology at Cornell University in Ithaca.  Our research group conducts epidemiological and translational studies and clinical trials. The clinical trials are conducted in the Weill Cornell HIV Clinical Trials Unit and are sponsored primarily by the NIH's Adult AIDS Clinical Trials Group (ACTG).  We also work closely with the NIH-funded Weill Cornell Clinical and Translational Science Center.

Highlights

  1. 1
    Psychosomatic medicine · 2022
    CJCarrie JohnstonYZYuan-Shan ZhuELEugenia L SieglerMJMarshall J. Glesby
    PMID: 35980785PMCID: PMC9553263DOISenior author19 citations
  2. 2
    Journal of general internal medicine · 2022
    SMSaurabh MehtaJCJustin ChoiMWMatthew William McCarthyAJAssem Jabri+4 more →MJMarshall J. Glesby
    PMID: 34997392PMCID: PMC8741546DOISenior author17 citations
  3. 3
    The journals of gerontology. Series B, Psychological sciences and social sciences · 2022
    CJCarrie JohnstonYZYuan-Shan ZhuELEugenia L SieglerMJMarshall J. Glesby
    PMID: 33580236PMCID: PMC8755907DOISenior author19 citations

Publications

225 publications

Funding

37 grantsView NIH portfolio on RePORTER ↗

Active

13 grants
  • KP
    Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)
    National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
    P30AI191337-01A1
  • Co-I
    Research Training in Infectious Diseases
    National Institute of Allergy and Infectious Diseases · 2014–2030· 3 renewals
    T32AI007613-26A1
  • Co-I
    Enhance II
    Administration for Community Living · 2024–2029
    90REGE0028-01-00
  • Sub-PI
    Northeast/ Caribbean AIDS Education and Training Centers - MAI
    Health Resources and Services Administration · 2024–2029 · via Columbia University
    5 TR7HA53197-02-00
  • Co-I
    PCORnet, the National Patient-Centered Clinical Research Network - INSIGHT Phase 4
    Patient-Centered Outcomes Research Institute · 2025–2028
    RI-CORNELL-01-PS8
  • Sub-PI
    Hormone Therapy for Peri- and Postmenopausal Women with HIV (HoT): ACTG A5424
    National Institute on Aging · 2025–2028 · via University of North Carolina at Chapel Hill
    R01AG081155-03
  • MPI
    Point of Care Technologies for Nutrition, Infection, and Cancer for Global Health (PORTENT)
    National Institute of Biomedical Imaging and Bioengineering · 2023–2028 · via Cornell University - Ithaca
    U54EB034654-03
  • MPI
    ACTG Leadership and Operations Center (LOC) - CRS 7803
    National Institute of Allergy and Infectious Diseases · 2011–2027 · via University of North Carolina at Chapel Hill· 11 renewals
    UM1AI068636-20
  • KP
    Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit
    National Institute of Allergy and Infectious Diseases · 2013–2027· 2 renewals
    UM1AI069419-15
  • KP
    Clinical and Translational Science Center - UL1
    National Center for Advancing Translational Sciences · 2017–2027· 2 renewals
    UL1TR002384-06
  • MPI
    1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
    National Heart, Lung, and Blood Institute · 2021–2026
    UG3HL154944-01A1
  • Sub-PI
    Northeast/ Caribbean AIDS Education and Training Centers - BASE
    Health Resources and Services Administration · 2024–2026 · via Columbia University
    5 TR7HA53197-02-00
  • Sub-PI
    The Women's Interagency HIV Study (WIHS) - V
    National Heart, Lung, and Blood Institute · 2019–2026 · via Yeshiva University
    U01HL146204-07
Completed grants (24)
  • KP
    International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) 018 STRIVE Platform Trial
    National Institute of Allergy and Infectious Diseases · 2022–2025 · via Institute for Clinical Research
    75N91020F00039/ 18X107CF6
  • Co-I
    Investigating Cellular Immunometabolic Mechanisms Underlying HIV-Related Cardiovascular Disease Risk
    National Heart, Lung, and Blood Institute · 2021–2025
    R01HL160392-01
  • MPI
    ACTG LOC (A5415 FDG PET/CT Scans)
    National Heart, Lung, and Blood Institute · 2023–2024 · via University of California, Los Angeles
    R01HL149516-03
  • Sub-PI
    INSIGHT Flu002: An International Observational Study to Characterize Adults with Influenza
    National Institute of Allergy and Infectious Diseases · 2009–2024 · via Institute for Clinical Research
    M38-CO-065-0910-4
  • Sub-PI
    DOHMH Special Projects Collaboration
    Health Resources and Services Administration · 2023–2024 · via Fund for Public Health in New York, Inc.
    FPH 230855-01
  • Sub-PI
    AIDS Education and Training Centers Program
    Health Resources and Services Administration · 2019–2024 · via Columbia University
    5 U1OHA29291-08-00
  • Sub-PI
    Supplement - AIDS Education and Training Centers Program
    Health Resources and Services Administration · 2019–2024 · via Columbia University
    6 U1OHA29291-06-01
  • MPI
    1/2 REPRIEVE Extension for Trial Completion
    National Heart, Lung, and Blood Institute · 2023–2024 · via The General Hospital Corporation (dba Massachusetts General Hospital)
    UG3HL164285-01
  • PI
    Clonal Hematopoeisis in HIV and Aging
    National Institute on Aging · 2020–2024
    R21AG066552-02
  • MPI
    Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: Uptown Site 7803 WB677 1560 B WB677
    National Institute on Aging · 2016–2023 · via University of California, Los Angeles· 2 renewals
    R01AG054366-06
  • MPI
    Pitavastatin to Reduce Physical Function Impairment and Frailty in HIV (PREPARE) - A5332 Substudy A5361s: Uptown Site 7803
    National Institute of Allergy and Infectious Diseases · 2014–2023 · via The General Hospital Corporation (dba Massachusetts General Hospital)
    U01HL123336-06
  • MPI
    Effect of Pitavastatin on Kidney Function in HIV-infected Persons - CRS 7803 1560 B XA867
    National Institute of Diabetes and Digestive and Kidney Diseases · 2016–2022 · via University of California, Los Angeles· 2 renewals
    R01DK108438-05
  • Sub-PI
    Ending the HIV Epidemic (Collaboration for CME Accreditation (AETC))
    Health Resources and Services Administration · 2020–2021 · via Public Health Solutions
    20-WCORNELL-01
  • Co-I
    Biopsychosocial pathways in aging with HIV: Investigating links between depression, stigma, inflammation, and health risks
    American Psychological Foundation · 2018–2020
    APF 183593-01
  • MPI
    Cardiovascular Disease Risk In HIV-Infected Women: Sex-Specific Mechanisms of Risk and Risk Reduction Among REPRIEVE Trial Participants
    National Institute of Allergy and Infectious Diseases · 2016–2020 · via The General Hospital Corporation (dba Massachusetts General Hospital)· 2 renewals
    R01AI123001-05
  • Sub-PI
    AIDS Education and Training Centers Program (AETC)
    Health Resources and Services Administration · 2015–2019 · via Columbia University
    5 U1O HA29291-02
  • Sub-PI
    INSIGHT FLU 006: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study
    National Institute of Allergy and Infectious Diseases · 2014–2019 · via Institute for Clinical Research
    M38-CO-065-0910-4
  • Co-I
    INSIGHT 001: Strategic Timing of AntiRetroviral Treatment (START)
    National Institute of Allergy and Infectious Diseases · 2010–2019 · via Institute for Clinical Research
    M38-CO-065-0910-4
  • Sub-PI
    The Women's Interagency HIV Study (WIHS) - V
    National Institute of Allergy and Infectious Diseases · 2008–2019 · via Yeshiva University· 3 renewals
    U01AI035004-26
  • KP
    Doxycycline for COPD in HIV-Infected Patients
    National Heart, Lung, and Blood Institute · 2012–2017
    R34HL117352-02 EW
  • PI
    Complications of Chronic Viral Infections
    NIAID · 2008–2014 · via NIH RePORTER
    K24AI078884-05
  • PI
    Growth Hormone and Rosiglitazone for Visceral Adoposity
    NIDDK · 2004–2011 · via NIH RePORTER
    R01DK065515-04
  • KP
    Natural History of Urban Leptospirosis
    National Institute of Allergy and Infectious Diseases · 2009–2010
    R01AI052473-06
  • MPI
    STUDY OF SAFETY AND EFFICACY OF RHGH A/O ROSIGLITAZONE IN HIV
    NCRR · 2004–2007 · via NIH RePORTER
    M01RR000047-47

Clinical research

19 studies

Active

3 studies
  • PI
    A5385: An Observational Post-Intervention Control Destination Cohort
    AIDS Clinical Trial Group · OPEN TO ACCRUAL (as of 2023)
  • PI
    Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Orthopoxvirus Infections
    Centers for Disease Control & Prevention · OPEN TO ACCRUAL (as of 2022)
  • PI
    Immunology Quality Assurance Program
    National Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2020)
Completed & closed trials (16)
  • PI
    SP-IND 179733 Compassionate Use of recombinant human Interleukin-7 (CYT107)
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)
  • PI
    A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease
    PHASE3 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)
    MPOX
    NCT05534984
  • PI
    Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
    PHASE2 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
    Emphysema; HIV
    NCT05382208
  • PI
    An Open Label, Single Arm Study of the Safety and Antiretroviral Activity of Two Long-acting Broadly Neutralizing Antibodies Plus an IL-15 Superagonist in ART-treated Adults Living With HIV During Analytical Treatment Interruption
    PHASE1 · Rockefeller University · IRB STUDY CLOSURE (as of 2025)
    Human Immunodeficiency Virus
    NCT05245292
  • PI
    A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
    PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)
    HIV-1-infection; Elevated Cardiovascular Risk
    NCT05630885
  • PI
    A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
    PHASE1 · National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2025)
    HIV Infection
    NCT04340596
  • PI
    Emergency IND: Brincidofovir (TEMBEXA)
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
    Centers for Disease Control & Prevention · IRB STUDY CLOSURE (as of 2025)
    Monkeypox; HIV Infections; AIDS
    NCT06045923
  • PI
    A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1
    PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)
    HIV Infections
    NCT03739996
  • PI
    A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals
    PHASE3 · National Institute of Allergy & Infectious Diseases · CLOSED TO ACCRUAL (as of 2024)
    HIV Infections
    NCT03635788
  • PI
    A Phase I, First-in-Human Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants With HIV
    PHASE1 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2023)
    HIV-1-infection
    NCT03705169
  • PI
    A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
    Hamilton Health Sciences Corporation · IRB STUDY CLOSURE (as of 2022)
    NCT04418518
  • PI
    A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation
    National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2021)
  • PI
    A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
    PHASE4 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2021)
    HIV Infections
    NCT02519777
  • PI
    An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19
    PHASE2; PHASE3 · Regeneron Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2021)
    COVID-19
    NCT04315298
  • PI
    An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
    PHASE2 · AIDS Clinical Trial Group · IRB STUDY CLOSURE (as of 2020)
    HIV Infections; Tuberculosis
    NCT03819114

News mentions

4 mentionsView all WCM news ↗
  • Faculty Honored with Notable Awards
    May 15, 2025

    Weill Cornell Medicine faculty members were honored with awards for their exemplary achievements in medical research, education and care May 14-15 during Weill Cornell Medicine’s commencement activities.

  • HIV Patients Fare Well with Mpox Treatment
    May 5, 2023

    Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat.

  • NIH Grant Funds Antibiotic Trial for Patients with HIV and Emphysema
    December 13, 2022

    Weill Cornell Medicine has been awarded a five-year, $7.8 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, to study whether the antibiotic doxycycline may slow the progression of the chronic lung disease emphysema in people living with well-controlled HIV.

  • NIAID Renews Weill Cornell Medicine Grant for Advancing Prevention and Treatment Research for HIV
    December 1, 2020

    Weill Cornell Medicine has received a renewal of a prestigious grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to continue cutting-edge clinical research into treating and preventing infection with human immunodeficiency virus (HIV).

Mentoring

1 menteeAll publications with mentees →

External relationships

Proprietary Interest

UpToDate, Inc.